Diclofenac + Paracetamol + Chlorzoxazone Tablets

• Raw Material Procurement and Testing: Den Mark Pharmaceuticals Pvt. Ltd. procures raw materials from approved suppliers, ensuring compliance with WHO GMP guidelines. Each batch of raw materials undergoes rigorous testing for identity, purity, potency, and quality parameters before acceptance for manufacturing process / production.
• Granulation: The first step involves granulating the active pharmaceutical ingredients (APIs) and excipients. Chlorzoxazone, Diclofenac, and Paracetamol are weighed accurately according to the formula (250mg, 50mg, and 325mg, respectively). These are mixed with appropriate excipients like binders, disintegrants, and lubricants to form a uniform blend. The blend is then granulated using a wet or dry granulation process to form granules of uniform size.
• Blending: The granules containing the APIs and excipients are blended thoroughly to ensure homogeneity. The blend is passed through a sieve to break any agglomerates and ensure uniformity in particle size distribution.
• Compression: The homogeneous blend is then compressed into tablets using high-quality tablet compression machines. The compression force and speed are optimized to ensure uniformity in the tablets' weight, thickness, and hardness.
• Coating (Optional): The Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets may undergo a coating process depending on the formulation requirements. The coating helps improve the tablets' stability, appearance, taste masking, and swallowability. A suitable coating solution containing polymers, plasticizers, and coloring agents is applied to the Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets using a coating pan or spray coating equipment.
• Quality Control Testing: Throughout the manufacturing process, in-process checks are conducted to ensure compliance with quality standards. Finished tablets undergo comprehensive quality control testing, including assays for API content, dissolution testing, uniformity of dosage units, friability, disintegration, and microbial limits as per WHO GMP guidelines.
• Packaging: Once the Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets pass all quality control tests, they are ready for packaging. Den Mark Pharmaceuticals Pvt. Ltd. utilizes high-quality packaging materials and automated packaging equipment to ensure product integrity and tamper-evidence. The Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets are packed into blister packs or bottles as per market requirements. Adequate labeling containing essential information such as product name, strength, batch number, expiry date, and storage conditions is applied to each unit.
• Storage and Distribution: The packaged Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets are stored in a controlled environment, complying with WHO GMP guidelines to maintain stability and efficacy. Den Mark Pharmaceuticals Pvt. Ltd. ensures proper documentation and traceability throughout the distribution process to guarantee the integrity of the product until it reaches the end consumer.

By following stringent manufacturing processes and adhering to WHO GMP guidelines, Den Mark Pharmaceuticals Pvt. Ltd. ensures the production of top-quality Chlorzoxazone (250mg) + Diclofenac (50mg) + Paracetamol (325mg) Tablets. The company's commitment to quality and compliance reflects its dedication to providing safe and effective pharmaceutical products to consumers worldwide.